JP Morgan Chase
MLYS icon

JP Morgan Chase’s Mineralys Therapeutics MLYS Stock Holding History

JP Morgan Chase’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.4M Sell
49,615
-2,307
-4% -$63.3K ﹤0.01% 4445
2026
Q1 		$1.22M Buy
51,922
+5,239
+11% +$154K ﹤0.01% 4471
2025
Q4 		$1.69M Sell
46,683
-136,997
-75% -$5.49M ﹤0.01% 4214
2025
Q3 		$6.97M Buy
183,680
+158,180
+620% +$3.42M ﹤0.01% 3065
2025
Q2 		$345K Buy
25,500
+4,946
+24% +$71.7K ﹤0.01% 4958
2025
Q1 		$326K Sell
20,554
-483,036
-96% -$5.56M ﹤0.01% 5025
2024
Q4 		$6.2M Buy
503,590
+482,174
+2,251% +$6.3M ﹤0.01% 3162
2024
Q3 		$259K Sell
21,416
-685
-3% -$8.29K ﹤0.01% 5289
2024
Q2 		$259K Buy
22,101
+3,363
+18% +$42.4K ﹤0.01% 5018
2024
Q1 		$242K Sell
18,738
-4,825
-20% -$59.6K ﹤0.01% 5248
2023
Q4 		$203K Buy
23,563
+14,479
+159% +$114K ﹤0.01% 5383
2023
Q3 		$86.4K Sell
9,084
-1,736
-16% -$22.6K ﹤0.01% 5576
2023
Q2 		$184K Buy
10,820
+1,551
+17% +$23.2K ﹤0.01% 5120
2023
Q1 		$145K Buy
+9,269
New +$156K ﹤0.01% 5255

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase's MLYS Position: Q2 2026 in Review

JP Morgan Chase reduced its Mineralys Therapeutics (MLYS) stake by 4.4% in Q2 2026, selling an estimated $63.3K and leaving 49,615 shares worth $1.4M. The position accounts for ﹤0.01% of the portfolio, ranked #4445.

JP Morgan Chase first reported a position in MLYS in Q1 2023 and has held it in 14 quarters since. The position peaked at $6.97M in Q3 2025. 225 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • JP Morgan Chase held 49,615 shares of Mineralys Therapeutics worth $1.4M as of Q2 2026.
  • JP Morgan Chase sold 2,307 Mineralys Therapeutics shares in Q2 2026, an estimated $63.3K.
  • Mineralys Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4445 holding.
  • JP Morgan Chase first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • JP Morgan Chase's Mineralys Therapeutics position peaked at $6.97M in Q3 2025.
  • 225 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.